ARCHIVES

Afinitor Increases Overall Survival To 3.5 Years in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

US, Italy Plan Greater Scientific Collaboration

May 16, 2003

Mayo Clinic Study Finds Samarium May Expand Options For Osteosarcoma

February 22, 2002

AACI Opposes Most Guidelines Proposals But Can’t Agree On Research Based Ceiling

May 2, 1980

Four Detroit Institutions Merge Cancer Clinical, Research Programs

July 15, 1994

B-27 Finds Improved CR For Taxotere Prior To Surgery

November 28, 2003

HHS Debars Straus, Who Concedes “Serious Deficiencies” In Trials

May 21, 1982